Anticonvulsant Effectiveness and Neurotoxicity Profile of 4-butyl-5-[(4-chloro-2-methylphenoxy)methyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione (TPL-16) in Mice.
Animals
Anticonvulsants
/ therapeutic use
Carbamazepine
/ therapeutic use
Drug Synergism
Male
Mice
Muscle Strength
/ drug effects
Phenobarbital
/ therapeutic use
Phenytoin
/ therapeutic use
Rotarod Performance Test
Seizures
/ drug therapy
Thiones
/ therapeutic use
Triazoles
/ therapeutic use
Valproic Acid
/ therapeutic use
1,2,4-triazole-3-thione
Antiepileptic drugs
Pharmacokinetic/pharmacodynamic interaction
Protective index
Tonic-clonic seizures
Journal
Neurochemical research
ISSN: 1573-6903
Titre abrégé: Neurochem Res
Pays: United States
ID NLM: 7613461
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
15
08
2020
accepted:
10
11
2020
revised:
11
10
2020
pubmed:
19
11
2020
medline:
10
8
2021
entrez:
18
11
2020
Statut:
ppublish
Résumé
Protective (antiseizure) effects of 4-butyl-5-[(4-chloro-2-methylphenoxy)-methyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione (TPL-16) and acute neurotoxic effects were determined in the tonic-clonic seizure model and rotarod test in mice. The interaction profile of four classic antiepileptic drugs (carbamazepine, phenobarbital, phenytoin and valproate) with TPL-16 was also determined in the tonic-clonic seizure model in mice. The protective effects of TPL-16 from tonic-clonic seizures (as ED
Identifiants
pubmed: 33206316
doi: 10.1007/s11064-020-03175-z
pii: 10.1007/s11064-020-03175-z
pmc: PMC7854423
doi:
Substances chimiques
Anticonvulsants
0
Thiones
0
Triazoles
0
Carbamazepine
33CM23913M
Valproic Acid
614OI1Z5WI
Phenytoin
6158TKW0C5
Phenobarbital
YQE403BP4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
396-410Subventions
Organisme : Narodowe Centrum Nauki
ID : UMO-2013/11/D/NZ7/01170
Références
Fiest KM, Sauro KM, Wiebe S et al (2017) Prevalence and incidence of epilepsy. Neurology 88:296–303. https://doi.org/10.1212/WNL.0000000000003509
doi: 10.1212/WNL.0000000000003509
pubmed: 27986877
pmcid: 5272794
Johnson EL (2019) Seizures and epilepsy. Med Clin North Am 103:309–324. https://doi.org/10.1016/j.mcna.2018.10.002
doi: 10.1016/j.mcna.2018.10.002
pubmed: 30704683
Moshé SL, Perucca E, Ryvlin P, Tomson T (2015) Epilepsy: new advances. Lancet 385:884–898. https://doi.org/10.1016/S0140-6736(14)60456-6
doi: 10.1016/S0140-6736(14)60456-6
pubmed: 25260236
Bialer M, Twyman RE, White HS (2004) Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav 5:866–872. https://doi.org/10.1016/j.yebeh.2004.08.021
doi: 10.1016/j.yebeh.2004.08.021
pubmed: 15582834
Stephen LJ, Brodie MJ (2012) Antiepileptic drug monotherapy versus polytherapy. Curr Opin Neurol 25:164–172. https://doi.org/10.1097/WCO.0b013e328350ba68
doi: 10.1097/WCO.0b013e328350ba68
pubmed: 22322411
Kalilani L, Sun X, Pelgrims B et al (2018) The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsia 59:2179–2193. https://doi.org/10.1111/epi.14596
doi: 10.1111/epi.14596
pubmed: 30426482
Löscher W, Klitgaard H, Twyman RE, Schmidt D (2013) New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov 12:757–776. https://doi.org/10.1038/nrd4126
doi: 10.1038/nrd4126
pubmed: 24052047
Kaur H, Kumar B, Medhi B (2016) Antiepileptic drugs in development pipeline: a recent update. eNeurologicalSci 4:42–51. https://doi.org/10.1016/j.ensci.2016.06.003
doi: 10.1016/j.ensci.2016.06.003
pubmed: 29430548
pmcid: 5803110
Bialer M, Johannessen SI, Koepp MJ et al (2018) Progress report on new antiepileptic drugs: a summary of the fourteenth Eilat conference on new antiepileptic drugs and devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia 59:1811–1841. https://doi.org/10.1111/epi.14557
doi: 10.1111/epi.14557
pubmed: 30368792
Meldrum BS, Rogawski MA (2007) Molecular targets for antiepileptic drug development. Neurotherapeutics 4:18–61. https://doi.org/10.1016/j.nurt.2006.11.010
doi: 10.1016/j.nurt.2006.11.010
pubmed: 17199015
pmcid: 1852436
Loron AG, Sardari S, Narenjkar J, Sayyah M (2017) In silico screening and evaluation of the anticonvulsant activity of docosahexaenoic acid-like molecules in experimental models of seizures. Iran Biomed J 21:32–39. https://doi.org/10.18869/acadpub.ibj.21.1.32
doi: 10.18869/acadpub.ibj.21.1.32
pmcid: 5141252
van Dijkman SC, Rauwé WM, Danhof M, Della Pasqua O (2018) Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children. Br J Clin Pharmacol 84:97–111. https://doi.org/10.1111/bcp.13400
doi: 10.1111/bcp.13400
pubmed: 28815754
Küçükgüzel G, Çikla-Süzgün P (2015) Recent advances bioactive 1,2,4-triazole-3-thiones. Eur J Med Chem 97:830–870. https://doi.org/10.1016/j.ejmech.2014.11.033
doi: 10.1016/j.ejmech.2014.11.033
pubmed: 25563511
Plech T, Kaproń B, Łuszczki JJ et al (2014) Studies on the anticonvulsant activity and influence on GABA-ergic neurotransmission of 1,2,4-triazole-3-thione-based compounds. Molecules 19:11279–11299. https://doi.org/10.3390/molecules190811279
doi: 10.3390/molecules190811279
pubmed: 25090118
pmcid: 6271529
Kaproń B, Łuszczki JJ, Siwek A et al (2020) Preclinical evaluation of 1,2,4-triazole-based compounds targeting voltage-gated sodium channels (VGSCs) as promising anticonvulsant drug candidates. Bioorg Chem 94:103355. https://doi.org/10.1016/j.bioorg.2019.103355
doi: 10.1016/j.bioorg.2019.103355
pubmed: 31662213
Plech T, Kaproń B, Łuszczki JJ et al (2014) Studies on the anticonvulsant activity of 4-alkyl-1,2,4-triazole-3-thiones and their effect on GABAergic system. Eur J Med Chem 86:690–699. https://doi.org/10.1016/j.ejmech.2014.09.034
doi: 10.1016/j.ejmech.2014.09.034
pubmed: 25226229
Verma KK, Singh UK, Jain J (2019) Design, synthesis and biological activity of some 4,5-disubstituted-2,4-dihydro-3H-1,2,4-triazole-3-thione derivatives. Cent Nerv Syst Agents Med Chem 19:197–205. https://doi.org/10.2174/1871524919666190722144424
doi: 10.2174/1871524919666190722144424
pubmed: 31749420
Kaproń B, Łuszczki J, Paneth A et al (2017) Molecular mechanism of action and safety of 5-(3-chlorophenyl)-4-hexyl-2,4-dihydro-3H-1,2,4-triazole-3-thione—a novel anticonvulsant drug candidate. Int J Med Sci 14:741–749. https://doi.org/10.7150/ijms.20001
doi: 10.7150/ijms.20001
pubmed: 28824309
pmcid: 5562128
Flieger J, Pizoń M, Plech T, Łuszczki JJ (2012) Analysis of new potential anticonvulsant compounds in mice brain tissue by SPE/HPLC/DAD. J Chromatogr B Anal Technol Biomed Life Sci 909:26–33. https://doi.org/10.1016/j.jchromb.2012.10.011
doi: 10.1016/j.jchromb.2012.10.011
Łuszczki JJ, Plech T, Wujec M (2012) Effect of 4-(4-bromophenyl)-5-(3-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur J Pharmacol 690:99–106. https://doi.org/10.1016/j.ejphar.2012.06.023
doi: 10.1016/j.ejphar.2012.06.023
pubmed: 22732650
Łuszczki JJ, Lepiech J, Zagaja M et al (2020) Anticonvulsant and neurotoxic effects of a novel 1,2,4-triazole-3-thione derivative (TPF-34) and its isobolographic interaction profile with classical antiepileptic drugs in mice. Pharmacol Rep 72:87–95. https://doi.org/10.1007/s43440-019-00044-7
doi: 10.1007/s43440-019-00044-7
pubmed: 32016835
Łuszczki JJ, Marzeda P, Gut-Lepiech A et al (2019) New derivative of 1,2,4-triazole-3-thione (TP427) potentiates the anticonvulsant action of valproate, but not that of carbamazepine, phenytoin or phenobarbital in the mouse tonic-clonic seizure model. Pharmacol Rep 71:299–305. https://doi.org/10.1016/j.pharep.2019.01.003
doi: 10.1016/j.pharep.2019.01.003
pubmed: 30826570
Wilcox KS, West PJ, Metcalf CS (2020) The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy. Neuropharmacology 166:107811. https://doi.org/10.1016/j.neuropharm.2019.107811
doi: 10.1016/j.neuropharm.2019.107811
pubmed: 31790717
Łuszczki JJ, Plech T, Wujec M (2012) Influence of 5-(3-chlorophenyl)-4-(4-methylphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione on the anticonvulsant action of 4 classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Pharmacol Rep 64:970–978. https://doi.org/10.1016/S1734-1140(12)70893-9
doi: 10.1016/S1734-1140(12)70893-9
pubmed: 23087150
Löscher W, Fassbender CP, Nolting B (1991) The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res 8:79–94. https://doi.org/10.1016/0920-1211(91)90075-q
doi: 10.1016/0920-1211(91)90075-q
pubmed: 2065646
Litchfield JT, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99–113
pubmed: 18152921
AVMA. AVMA Guidelines for the Euthanasia of Animals: 2020 Edition: American Veterinary Medical Association; 2020. Available from: https://www.avma.org/sites/default/files/2020-01/2020-Euthanasia-Final-1-17-20.pdf
Huang RY, Pei L, Liu Q et al (2019) Isobologram analysis: a comprehensive review of methodology and current research. Front Pharmacol 10:1–12. https://doi.org/10.3389/fphar.2019.01222
doi: 10.3389/fphar.2019.01222
Gessner PK (1995) Isobolographic analysis of interactions: an update on applications and utility. Toxicology 105:161–179. https://doi.org/10.1016/0300-483x(95)03210-7
doi: 10.1016/0300-483x(95)03210-7
pubmed: 8571354
Tallarida RJ (2016) Drug combinations: tests and analysis with isoboles. Curr Protoc Pharmacol 72:9.19.1–9.19.19. https://doi.org/10.1002/0471141755.ph0919s72
doi: 10.1002/0471141755.ph0919s72
Tallarida RJ (2002) The interaction index: a measure of drug synergism. Pain 98:163–168. https://doi.org/10.1016/s0304-3959(02)00041-6
doi: 10.1016/s0304-3959(02)00041-6
pubmed: 12098628
Boissier JR, Tardy J, Diverres JC (1960) Une nouvelle méthode simple pour explorer l’action “tranquillisante”: le test de la cheminée. Pharmacology 3:81–84
doi: 10.1159/000134913
Meyer OA, Tilson HA, Byrd WC, Riley MT (1979) A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav Toxicol 1:233–236
pubmed: 551317
Kehne JH, Klein BD, Raeissi S, Sharma S (2017) The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP). Neurochem Res 42:1894–1903. https://doi.org/10.1007/s11064-017-2275-z
doi: 10.1007/s11064-017-2275-z
pubmed: 28462454
pmcid: 5504134
Luszczki JJ, Karpińska M, Matysiak J, Niewiadomy A (2015) Characterization and preliminary anticonvulsant assessment of some 1,3,4-thiadiazole derivatives. Pharmacol Rep 67:588–592. https://doi.org/10.1016/j.pharep.2014.12.008
doi: 10.1016/j.pharep.2014.12.008
pubmed: 25933973
Kocharov SL, Panosyan H, Chmielewski J et al (2019) Synthesis and anticonvulsant properties of some n-aryl and n-arylaminomethyl derivatives of 3-p-isopropoxyphenylpyrrolidine-2,5-dione. Acta Pol Pharm Drug Res 76:265–273. https://doi.org/10.32383/appdr/97323
doi: 10.32383/appdr/97323
Świąder MJ, Paruszewski R, Łuszczki JJ (2016) Assessment of the anticonvulsant potency of various benzylamide derivatives in the mouse maximal electroshock-induced seizure threshold model. Pharmacol Rep 68:259–262. https://doi.org/10.1016/j.pharep.2015.09.003
doi: 10.1016/j.pharep.2015.09.003
pubmed: 26922525
Herman TF, Santos C (2020) First pass effect. In: StatPearls [internet]. StatPearls Publishing, Treasure Island
Porter RJ, Kupferberg HJ (2017) The Anticonvulsant Screening Program of the National Institute of Neurological Disorders and Stroke, NIH: history and contributions to clinical care in the twentieth century and beyond. Neurochem Res 42:1889–1893. https://doi.org/10.1007/s11064-017-2215-y
doi: 10.1007/s11064-017-2215-y
pubmed: 28275952
Porter RJ, Kupferberg HJ, Hessie BJ (2015) Mechanisms of action of anti-seizure drugs and the anticonvulsant screening program of the National Institute of Neurological Disorders and Stroke. Int J Clin Pharmacol Ther 53:9–12. https://doi.org/10.5414/CP202212
doi: 10.5414/CP202212
pubmed: 25407259
Plech T, Luszczki JJ, Wujec M et al (2013) Synthesis, characterization and preliminary anticonvulsant evaluation of some 4-alkyl-1,2,4-triazoles. Eur J Med Chem 60:208–215. https://doi.org/10.1016/j.ejmech.2012.11.026
doi: 10.1016/j.ejmech.2012.11.026
pubmed: 23291122
Festing MFW, Altman DG (2002) Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J 43:244–258. https://doi.org/10.1093/ilar.43.4.244
doi: 10.1093/ilar.43.4.244
pubmed: 12391400
Kilkenny C, Parsons N, Kadyszewski E et al (2009) Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One 4:e7824. https://doi.org/10.1371/journal.pone.0007824
doi: 10.1371/journal.pone.0007824
pubmed: 19956596
pmcid: 2779358
McGrath JC, Drummond GB, McLachlan EM et al (2010) Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160:1573–1576
doi: 10.1111/j.1476-5381.2010.00873.x
pubmed: 20649560
pmcid: 2936829
Mascha EJ, Vetter TR (2018) Significance, errors, power, and sample size: the blocking and tackling of statistics. Anesth Analg 126:691–698. https://doi.org/10.1213/ANE.0000000000002741
doi: 10.1213/ANE.0000000000002741
pubmed: 29346210
Łuszczki JJ (2009) Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep 61:197–216. https://doi.org/10.1016/s1734-1140(09)70024-6
doi: 10.1016/s1734-1140(09)70024-6
pubmed: 19443931
Klitgaard H, Matagne A, Gobert J, Wülfert E (1998) Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353:191–206. https://doi.org/10.1016/s0014-2999(98)00410-5
doi: 10.1016/s0014-2999(98)00410-5
pubmed: 9726649
Kilkenny C, Browne W, Cuthill IC et al (2010) Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160:1577–1579. https://doi.org/10.1111/j.1476-5381.2010.00872.x
doi: 10.1111/j.1476-5381.2010.00872.x
pubmed: 20649561
pmcid: 2936830
Luszczki JJ, Czuczwar SJ (2003) Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics—a comparative study. Epilepsy Res 56:27–42. https://doi.org/10.1016/j.eplepsyres.2003.08.003
doi: 10.1016/j.eplepsyres.2003.08.003
pubmed: 14529951
Luszczki JJ, Czuczwar SJ (2006) Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis. Naunyn Schmiedeberg’s Arch Pharmacol 374:51–64. https://doi.org/10.1007/s00210-006-0100-3
doi: 10.1007/s00210-006-0100-3
Luszczki JJ, Danysz W, Czuczwar SJ (2008) Interactions of MRZ 2/576 with felbamate, lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model. Pharmacology 81:259–265. https://doi.org/10.1159/000114870
doi: 10.1159/000114870
pubmed: 18253065
Brodie MJ, Sills GJ (2011) Combining antiepileptic drugs—rational polytherapy? Seizure 20:369–375. https://doi.org/10.1016/j.seizure.2011.01.004
doi: 10.1016/j.seizure.2011.01.004
pubmed: 21306922
Janmohamed M, Brodie MJ, Kwan P (2020) Pharmacoresistance—epidemiology, mechanisms, and impact on epilepsy treatment. Neuropharmacology 168:107790. https://doi.org/10.1016/j.neuropharm.2019.107790
doi: 10.1016/j.neuropharm.2019.107790
pubmed: 31560910
Hitiris N, Mohanraj R, Norrie J et al (2007) Predictors of pharmacoresistant epilepsy. Epilepsy Res 75:192–196. https://doi.org/10.1016/j.eplepsyres.2007.06.003
doi: 10.1016/j.eplepsyres.2007.06.003
pubmed: 17628429
Perucca E (1995) Pharmacological principles as a basis for polytherapy. Acta Neurol Scand Suppl 162:31–34. https://doi.org/10.1111/j.1600-0404.1995.tb00497.x
doi: 10.1111/j.1600-0404.1995.tb00497.x
pubmed: 7495187
French JA, Faught E (2009) Rational polytherapy. Epilepsia 50(Suppl 8):63–68. https://doi.org/10.1111/j.1528-1167.2009.02238.x
doi: 10.1111/j.1528-1167.2009.02238.x
pubmed: 19702736
Tomson T, Battino D, Perucca E (2016) Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol 15:210–218. https://doi.org/10.1016/S1474-4422(15)00314-2
doi: 10.1016/S1474-4422(15)00314-2
pubmed: 26655849
Löscher W (2002) Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16:669–694. https://doi.org/10.2165/00023210-200216100-00003
doi: 10.2165/00023210-200216100-00003
pubmed: 12269861
Luszczki JJ, Mohamed M, Czuczwar SJ (2006) 2-Phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. Eur J Pharmacol 531:66–73. https://doi.org/10.1016/j.ejphar.2005.11.045
doi: 10.1016/j.ejphar.2005.11.045
pubmed: 16403497